CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma

Clinical Cancer Research

Volumn 14, Issue 9, 2008, Pages 2775-2784

  Hsi, Eric D ^a   Steinle, Roxanne ^a   Balasa, Balaji ^b   Szmania, Susann ^c   Draksharapu, Aparna ^b   Shum, Benny P ^b   Huseni, Mahrukh ^b   Powers, David ^b   Nanisetti, Amulya ^b   Zhang, Yin ^b   Rice, Audie G ^b   Van Abbema, Anne ^b   Wong, Melanie ^b   Liu, Gao ^b   Zhan, Fenghuang ^c   Dillon, Myles ^b   Chen, Shihao ^b   Rhodes, Susan ^b   Fuh, Franklin ^b   Tsurushita, Naoya ^b   Kumar, Shankar ^b   Vexler, Vladimir ^b   Shaughnessy Jr , John D ^c   Barlogie, Bart ^c   Van Rhee, Frits ^c   Hussein, Mohamad ^d   Afar, Daniel E H ^b   Williams, Marna B ^b   more..

^a LERNER RESEARCH INSTITUTE   (United States)

^b PDL BioPharma Inc   (United States)

^c UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD34 ANTIGEN; CELL SURFACE PROTEIN; HULUC63 ANTIBODY; MESSENGER RNA; MONOCLONAL ANTIBODY; PROTEIN CS1; RITUXIMAB; UNCLASSIFIED DRUG; IMMUNOGLOBULIN RECEPTOR; SLAMF7 PROTEIN, HUMAN;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW BIOPSY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOGENETICS; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NATURAL KILLER CELL; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; CYTOLOGY; DRUG SCREENING; GENETICS; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; METABOLISM; MOUSE MUTANT; PLASMA CELL; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; MICE; MICE, SCID; MULTIPLE MYELOMA; PLASMA CELLS; RECEPTORS, IMMUNOLOGIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 52049104695     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4246     Document Type: Article

References (49)

1. SEER Cancer Statistics Review, 1975-2002. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Clegg L, et al., editors. 2002. Bethesda (MD): National Cancer Institute.
2. Hari P, Pasquini MC, Vesole DH. Cure of multiple myeloma - more hype, less reality. Bone Marrow Transplant 2006;37:1 -18.
3. Greipp P. Treatment paradigms for the newly diagnosed patient with multiple myeloma. Semin Hematol 2005;42:S16-21.
4. Crane E, List A. Immunomodulatory drugs. Cancer Invest 2005;23:625-34.
5. Gahrton G, lacobelli S, Bjorkstrand B, et al. Role of stem cell transplantation in myeloma. Hematology 2005;10 Suppl 1:127-8.
6. Anderson KC. Lenalidomide and thalidomide: mechanisms of action-similarities and differences. Semin Hematol 2005;42:S3-8.
7. Held G, Poschel V, Pfreundschuh M. Rituximab for the treatment of diffuse large B-cell lymphomas. Expert Rev Anticancer Ther 2006;6:1175-86.
8. HabermannTM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121 -7.
9. Buske C, Hiddemann W. Rituximab maintenance therapy in indolent NHL: a clinical review. Leuk Res 2006;30 Suppl1:S11 -5.
10. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MlnT) Group. Lancet Oncol 2006;7:379-91.
11. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013-23.
12. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma tudy Group. Blood 2005:106:3725-32.
13. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
14. Czuczman MS. CHOP plus rituximab chemoimmu-notherapy of indolent B-cell lymphoma. Semin Oncol 1999;26:88-96.
15. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-76.
16. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000;18:317-24.
17. Marshall H. Anti-CD20 antibody therapy is highly effective in the treatment of follicular lymphoma. Trends Immunol 2001;22:183-4.
18. Kumaresan PR, Lai WC, Chuang SS, Bennett M, Mathew PA. CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function. Mol Immunol 2002;39:1 -8.
19. Bhat R, Eissmann P, Endt J, Hoffmann S.Watzl C. Fine-tuning of immune responses by SLAM-related receptors. J Leukoc Biol 2006;79:417-24.
20. Eissmann P, Beauchamp L, Wooters J, Tilton JC, Long EO, Watzl C. Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244). Blood 2005;105:4722-9.
21. Shlapatska LM, Mikhalap SV, Berdova AG, et al. CD150 association with either the SH2-containing inositol phosphatase or the SH2-containing protein tyrosine phosphatase is regulated by the adaptor protein SH2D1A. J Immunol 2001;166:5480-7.
22. Hubank M, Schatz DG. Identifying differences in mRNA expression by representational difference analysis of cDNA. Nucleic Acids Res 1994;22:5640-8.
23. O'Hara EF, Williams MB, Rott L, et al. Modified representational difference analysis: isolation of differentially expressed mRNAs from rare cell populations. Anal Biochem 2005;336:221 -30.
24. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood 2006;108:2020-8.
25. Henshall SM, Afar DE, Hiller J, et al. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 2003;63:4196-203.
26. Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A 1989;86:10029-33.
27. Kilmartin JV, Wright B, Milstein C. Rat monoclonal antitubulin antibodies derived by using a new nonse-creting rat cell line. J Cell Biol 1982;93:576 -82.
28. ShinkawaT, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003;278:3466-73.
29. Xu D, Alegre ML, Varga SS, et al. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol 2000;200:16-26.
30. Drobyski WR, Gottlieb M, Carrigan D, et al. Phase I study of safety and pharmacokinetics of a human anti-cytomegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients. Transplantation 1991;51:1190-6.
31. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hemat- other1996;5:213-26.
32. Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody Hu Luc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. Epub 2007 Oct 10.
33. Boles KS, Mathew PA. Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily. Immunogenetics 2001;52:302-7.
34. Bouchon A, Cella M, Grierson HL, Cohen Jl, Colonna M. Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. J Immunol 2001;167:5517-21.
35. Henshall SM, Afar DE, Rasiah KK, et al. Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene 2003;22:6005-12.
36. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95.
37. Vugmeyster Y, Howell K, Bakshl A, Flores C, Canova-Davis E. Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix. Cytometry A 2003;52: 101-9.
38. Brett S, Baxter G, Cooper H, Johnston JM, Tite J, Rapson N. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H. Immunology 1996;88:13-9.
39. Shultz LD, Lyons BL, Burzenski LM, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R γnułl mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005;174:6477-89.
40. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006;354:1021 -30.
41. Chilosi M, Adami F, Lestani M, et al. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Mod Pathol 1999;12:1101-6.
42. O'Connell FP, Pinkus JL, Pinkus GS. CD138 (syndecan-1), a plasma cell marker immunohisto-chemical profile in hematopoietic and nonhemato-poietic neoplasms. Am J Clin Pathol 2004;121:254-63.
43. Cagnoni F, Oddera S, Giron-Michel J, et al. CD40 on adult human airway epithelial cells: expression and proinflammatory effects. J Immunol 2004;172:3205-14.
44. GalyAH, Spits H. CD40 is functionally expressed on human thymic epithelial cells. J Immunol 1992;149:775-82.
45. Iwata M, Soya K, Sawa M, SakimotoT, Hwang DG. CD40 expression in normal human cornea and regulation of CD40 in cultured human corneal epithelial and stromal cells. Invest Ophthalmol Vis Sci 2002;43:348-57.
46. Palmer DH, Hussain SA, Ganesan R, et al. CD40 expression in prostate cancer: a potential diagnostic and therapeutic molecule. Oncol Rep 2004;12:679-82.
47. Pammer J, Weninger W, Mazal PR, Horvat R, Tschachler E. Expression of the CD40 antigen on normal endothelial cells and in benign and malignant tumours of vascular origin. Histopathology 1996;29:517-24.
48. Sugiura T Kawaguchi Y, Harigai M, et al. Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoat-tractant protein-1 production. J Immunol 2000;164:6593-600.
49. Vyth-Dreese FA, Dellemijn TA, Majoor D, de Jong D. Localization in situ of the co-stimulatory molecules B7.1, B7.2, CD40 and their ligands in normal human lymphoid tissue. Eur J Immunol 1995;25:023-9.